

and computer readable form of the Sequence Listing. It is also respectfully requested that the application be amended as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 6, under the heading --Detailed Disclosure--, please rewrite the paragraph thereat as follows:

Hence, one embodiment of the invention pertains to a fusion polypeptide which comprises a first amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the *M. tuberculosis* protein ESAT-6 (SEQ ID NO: 1), and a second amino acid sequence including at least one stretch of amino acids constituting a T-cell epitope derived from the *M. tuberculosis* protein Ag85B and/or a stretch of amino acids which protects the first amino acid sequence from *in vivo* degradation or post-translational processing (SEQ ID NO: 2). The first amino acid sequence may be situated N- or C-terminally to the second amino acid sequence, but in line with the above considerations regarding protection of the ESAT-6 N-terminus, it is preferred that the first amino acid sequence is C-terminal to the second.

Please cancel the previously submitted pages identified as --Sequence Listing--.

Immediately after page 51 and before the first page of claims (page 52), please insert the enclosed pages identified as --Sequence Listing--;

REQUEST FOR EXTENSION OF TIME

Pursuant to 37 C.F.R. §1.136(a), Applicant hereby requests a three-month extension of the period for response to the Office Action, mailed April 10, 2001, i.e., up to and including October 10, 2001.

Submitted herewith is a check in the amount of \$1440.00 to cover the cost of this Petition. The Commissioner is hereby authorized to charge any deficiency or credit any overpayment in this Petition fee to Deposit Account No. 50-0320.